Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer.
Local immunotherapy resurfaces in the field of cancer as a potential way to cure localized and metastatic disease with limited toxic effects. We have recently demonstrated that local administration of agonistic CD40 antibodies can cure localized as well as disseminated bladder neoplasms. This approach reduces the circulating concentrations of antibodies that would result from systemic delivery, hence resulting in limited toxicity.
Department of Immunology, Genetics and Pathology; Uppsala University; Uppsala, Sweden.
Linda C
LC
Sandin
Department of Immunology, Genetics and Pathology; Uppsala University; Uppsala, Sweden.
Thomas H
TH
Tötterman
Department of Immunology, Genetics and Pathology; Uppsala University; Uppsala, Sweden.
Sara M
SM
Mangsbo
CD40; antibody; bladder cancer; local immunotherapy